EVALUATING THE COST-EFFECTIVENESS OF DIFFERENT GROUPS OF HYPERTENSION THERAPY: A PHARMACOECONOMIC STUDY

Roobena Parveen A; Vara Prasanna Rao M

doi:10.22159/ajpcr.2018.v11s4.31738

Authors

Roobena Parveen A Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University, Pallavaram, Chennai - 600 043, Tamil Nadu, India.
Vara Prasanna Rao M Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University, Pallavaram, Chennai - 600 043, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11s4.31738

Keywords:

Antihypertensive, Cost-effectiveness, Systolic blood pressure, Diastolic blood pressure

Abstract

Objective: The study objective is to evaluate among the different groups of antihypertensive for their cost-effectiveness and to provide information about the effective management of hypertensives both clinically and economically.

Methods: This study involves 81 patients aged 18â€“80 years on antihypertensive treatment who were enrolled from December to May with daily dose calculation. It is performed to analyze cost-effectiveness in the management of clinical condition. Data collection form to be entered with age, sex, food habits, occupational status, clinical data, and drugs was used for treatment. Incremental cost-effectiveness ratio is calculated based on the incremental cost for per mmHgâ€ reduction and cost for per patientâ€ reaching target blood pressure (BP).

Result: Angiotensin receptor blockers (ARBs) show a significant average reduction of systolic BP (SBP) and beta-blockers (BBs) show an average reduction of diastolic BP (DBP). Angiotensin-converting enzyme inhibitors (ACEIs) are cost effective in SBP and calcium channel blockers are cost effective in maintaining DBP.

Conclusion: ARBs, BBs, and ACEIs show the effective management of hypertensives both clinically and economically.

Downloads

Download data is not yet available.

References

WHO. A Global Brief on Hypertension Silent killer, Global Public Health Crisis. Geneva, Switzerland: WHO; 2013.

Sharma SK, Sawhney V. Awareness, stress, anxiety, and depression among hypertensive patients attending cardiac outpatient department in a super specialty hospital. Asian J Pharm Clin Res 2016;9:62-4.

Reaven GM. Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 1991;90:7S-12S.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560-72.

Drummond M, JÃ¶nsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997;40:199-215.

Frick KD. Understanding cost-outcome analysis for interventions dealing with unpleasant symptoms. Adv Stud Nurs 2005;3:158-63.

Tsokeva ZH, Sokolova K, Radev S. Pharmacoeconomics in evaluating health care decisions. Trakia J Sci 2006;4:9-13.

Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: Costs â€“ moving beyond the acquisition price for drugs. J Clin Pharm Ther 2003;28:73-9.

Bevan D. Pharmacoeconomics: Cost effective choices. Int Anesth Res Soci Can J Anaesth 1993;40:693-5

Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.